BioTime launches all-stock bid to acquire Geron's stalled stem cell programme
This article was originally published in Clinica
Executive Summary
After hiring Geron's former president and CEO to run an acquisition-focused subsidiary, BioTime has made a public bid for the regenerative medicine programme that Geron put on hold almost a year ago, offering an all-stock deal for embryonic stem cell technology previously investigated as a treatment for acute spinal cord injuries.